<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383068</url>
  </required_header>
  <id_info>
    <org_study_id>[2017]055</org_study_id>
    <nct_id>NCT03383068</nct_id>
  </id_info>
  <brief_title>Research of Intensive Metabolic Intervention Before Pregnancy in PCOS</brief_title>
  <acronym>PCOS</acronym>
  <official_title>Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether intensive metabolic intervention of PCOS women before pregnancy can
      improve pregnancy outcome.Besides, the investigators aim to investigate the best therapy
      strategy of metabolic intervention before pregnancy.The investigators plan to recruit PCOS
      women at childbearing age. By using acarbose, GLP-1 analogue, berberin et al. the
      investigators will intervent the participants' metabolic statues for 3 months before
      pregnancy and to compare outcome in each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate whether intensive metabolic intervention of PCOS women before pregnancy can
      improve pregnancy outcome.Besides, the investigators aim to investigate the best therapy
      strategy of metabolic intervention before pregnancy.The investigators plan to recruit PCOS
      women with IGR / DM not effective of metformin treatment at childbearing age. By using
      acarbose, GLP-1 analogue, berberin et al. the investigators will intervent the participants'
      metabolic statues for 3 months before pregnancy and to compare outcome in each group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of pregnant rate after intensive metabolic intervention</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the pregnant rate of four groups after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of obsorbtion rate after intensive metabolic intervention</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the obsorbtion rate of four groups after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of stillborn foetus rate after intensive metabolic intervention</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the stillborn foetus rate of four groups after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of hyperandrogenism</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the free androgen index of three groups after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the intravenous blood glucose of three groups after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of triglyceride</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To compare the circulating triglyceride of three groups after treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>PCOS</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10Î¼g/bid ) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose 100 MG</intervention_name>
    <description>for metformin uneffective subjects, using acarbose for 3 months</description>
    <arm_group_label>acarbose</arm_group_label>
    <other_name>Acarbose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>for metformin uneffective subjects, using Exenatide for 3 months</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>for metformin uneffective subjects, using Orlistatfor 3 months</description>
    <arm_group_label>Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin effective subjects,act as control group</description>
    <arm_group_label>control</arm_group_label>
    <other_name>METF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS women at Childbearing Age

          -  PCOS: Clinical hyperandrogenism and/or hyperandrogenemia, menstrual dysfunction
             (oligomenorrhea or amenorrhea) and exclusion of other known disorders. PCOS will be
             diagnosed using the 2003 Rotterdam criteria.

        Exclusion Criteria:

          -  Past or present history of a medical disorder or medication known to affect body
             composition, insulin secretion and sensitivity, or the growth hormone
             (GH)-insulin-like growth factor 1 (IGF1) axis (eg steroid hormone or thyroid
             replacement).

          -  History of current or past pregnancy

          -  Hormonal contraceptive or metformin use within 3 months of enrollment

          -  Nonclassical congenital adrenal hyperplasia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Tao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Tao, MD</last_name>
    <phone>86-13817701776</phone>
    <email>taotaosh76@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital Department of Endocrinology and Metabolism</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Liu, MD</last_name>
      <phone>+86-18918358342</phone>
      <email>sue_liuwei@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>imparied glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

